MTOR and cancer: In the later stages, CIN II and CIN III, there was more enrichment in cancer-related signaling pathways, including transforming growth factor (TGF)-beta, mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), and RAS signaling as shown in a heatmap (Figure 5).